曲美他嗪治疗冠心病合并慢性心功能不全的临床研究被引量：4

下载PDF

导出

摘要目的观察曲美他嗪治疗冠心病合并慢性心功能不全的疗效。方法将114例冠心病合并慢性心功能不全患者分为两组,各57例。对照组给予常规药物治疗,研究组在对照组治疗基础上加用曲美他嗪20 mg口服治疗,3次/d,疗程3个月。治疗前后测定两组患者血浆N末端B型利钠肽原(NT-proBNP)水平、6min步行距离,并评价心功能和心脏超声指标改善情况。结果研究组总有效率高于对照组(P<0.05)。两组治疗后NT-proBNP水平均较治疗前低,6min步行距离延长,但研究组改善更明显(均P<0.05)。两组治疗后左室收缩末期内径、左室舒张末期内径均较治疗低,左室射血分数、二尖瓣口舒张早期和舒张晚期血流峰值之比高,但研究组改善更明显(均P<0.05)。结论曲美他嗪治疗冠心病合并慢性心功能不全临床疗效确切,能提高心功能和运动耐力,改善左室重构。

作者严冰

机构地区湖州市第一人民医院

出处《现代实用医学》 2014年第3期279-280,310,共3页 Modern Practical Medicine

关键词冠状动脉硬化心功能不全药物疗法曲美他嗪

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Demirelli S, Karakelleoglu S, Gundogdu F, et al. The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention[J].Korean Cire J,2013,43(7): 462-467.
2Nassar Y, Boudou N, Carrie D, et al. Radi- al approach and single wiring as first in- tentional strategies in chronic total occlusions of the lett anterior descending coronary artery[J].J Saudi Heart Assoc,2013,25(2): 67-73.
3何洪月,岳丽,李秀霞.麝香保心丸联合曲美他嗪治疗老年缺血性心肌病心力衰竭的疗效观察[J].中国全科医学,2010,13(18):2034-2035. 被引量：96
4许晓晗,张维君,周玉杰,周志明,马涵英,胡宾,康云鹏,雒芳芳.曲美他嗪对经皮冠状动脉介入治疗相关心肌损伤及术后左心功能的影响[J].中华心血管病杂志,2013,41(3):205-209. 被引量：25
5Ferraro E, Giammarioli AM, Caldarola S, et al. The metabolic modulator trimetazi- dine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes[J].FEBS J,2013,280(20):5094-5108.
6Li L, Wang L, Shao Y, et al. Elucidation of release characteristics of highly soluble drug trimetazidine hydrochloride from chit- osan-carrageenan matrix tablets[J].J Pharm Sci,2013,102(8):2644-2654.

二级参考文献18

1柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2136
2Fuchs S, Gruberg L, Singh S, et al. Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndrome. Am J Cardiol, 2001,88 : 129-133.
3Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percntaneous coronary intervention. J Am Coll Cardiol, 2002, 39: 1738-1744.
4Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart, 2007,93 : 703-707.
5Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs, 2007,7 : 143-150.
6Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation, 2001,104:2436-2441.
7Grube E, Gerckens U, Yeung AC, et aI. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous fiher protection. Circulation, 2001, 104:2436-2441.
8Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long- chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000,86 : 580- 588.
9Bucei M, Bona R, Ngtgren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther, 2012,30:333-341.
10Zhou X, Li C, Xu W, et al. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One, 2012, 7 : e40424.